Madsen Ole Rintek, Egsmose Charlotte
Reumatologisk Klinik, Medicinsk Afdeling C, Gentofte Hospital, DK-2900 Hellerup.
Ugeskr Laeger. 2009 Aug 10;171(33):2268-72.
Ankylosing spondylitis (AS) is an inflammatory disorder affecting the axial skeleton, peripheral joints, entheses and extra-articular sites. Patients with early disease, a higher level of erythrocyte sedimentation rate and/or peripheral arthritis might benefit from sulfasalazine. Otherwise, there is no evidence that disease-modifying anti-rheumatic (DMARDs) have a therapeutic effect in AS. Clinical evidence that greater TNF-inhibitor effectiveness can be achieved by combining with a DMARD is lacking, but further studies should be performed. More research is needed to clarify the role of DMARDs in the treatment of AS.
强直性脊柱炎（AS）是一种影响中轴骨骼、外周关节、附着点和关节外部位的炎性疾病。疾病早期、红细胞沉降率较高和/或患有外周关节炎的患者可能从柳氮磺胺吡啶中获益。否则，没有证据表明改善病情抗风湿药（DMARDs）对AS有治疗作用。缺乏关于联合使用DMARDs可提高肿瘤坏死因子（TNF）抑制剂疗效的临床证据，但应开展进一步研究。需要更多研究来阐明DMARDs在AS治疗中的作用。
